We really like the underlying value of this company and it's consistent track record for earnings shows us that the company may be a big sleeper in our value investing strategies.
http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/04-18-2007/0004568817&EDATE=
spreva Pharmaceuticals Corporation (Aspreva) is a pharmaceutical company focused on identifying, developing and commercializing existing approved drugs and drug candidates for new indications. The Company's focus is on delivering treatments to manage less common diseases. Aspreva has entered into collaboration with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd (collectively referred to as Roche) for exclusive worldwide rights, excluding Japan, to develop and commercialize CellCept for all autoimmune indications. CellCept is Roche's immunosuppressant or anti-rejection drug used in combination with other immunosuppressive drugs, such as cyclosporine and corticosteroids, for the prevention of rejection in patients receiving heart, kidney and liver transplants.
$22.33 (04/20/07)
